Target intelligence / Profile preview

Gut microbiome and mucosal environment

Molecular classification
Other
01

Overview

The gut microbiome and mucosal environment represent a complex biological system comprising trillions of commensal microorganisms and the protective mucus layer of the intestinal tract. This ecosystem performs vital functions, including the fermentation of dietary fibers into short-chain fatty acids (SCFAs), synthesis of vitamins K and B12, and the regulation of the host's mucosal immune system (NIH, PMC3426293). The mucosal barrier serves as a critical interface, preventing the translocation of pathogens while allowing for nutrient absorption and signaling between the microbiota and the host (Nature Reviews Gastroenterology & Hepatology, 2014). Dysbiosis, or the functional imbalance of this ecosystem, is a key driver in the development of gastrointestinal disorders like Inflammatory Bowel Disease (IBD) and systemic conditions such as obesity and type 2 diabetes (PubMed, 24336217). Therapeutic interventions targeting this environment include antibiotics to eliminate pathogens, prebiotics to nourish beneficial bacteria, and live biotherapeutic products (LBPs) like SER-109 designed to restore ecological diversity (FDA, 2023). Unlike traditional single-molecule targets, modulating the gut microbiome requires a systems-biology approach to restore the complex interactions between microbial species and the host's epithelial and immune cells (Cell, 2019).

Other names
Gut microbiotaIntestinal microbiomeGut mucosal barrierIntestinal microfloraGastrointestinal ecosystem
02

Mechanism of action

Restoration of microbial diversity, competitive exclusion of pathogens, modulation of host immune signaling through Toll-like receptors, and production of bioactive metabolites such as short-chain fatty acids (SCFAs) and bile acid derivatives.

03

Biological functions

MetabolismImmune responseBarrier functionVitamin synthesisPathogen defense
04

Disease associations

Inflammatory bowel diseaseObesityDiabetes mellitusColorectal cancerClostridioides difficile infectionNeurodegenerative disease
05

Safety considerations

Risk of opportunistic infectionTransfer of antibiotic resistance genesSystemic translocation of bacteriaLong-term ecological disruption
06

Interacting drugs

Fecal microbiota spores, live-brpk (SER-109)

5 more in the full profile.

07

Biomarkers

Microbial alpha diversityFirmicutes/Bacteroidetes ratioFecal calprotectinShort-chain fatty acid levelsAkkermansia muciniphila abundance

Beyond the preview

Go deeper on Gut microbiome and mucosal environment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut microbiome and mucosal environment.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call